A B S T R A C T Antileukocyte antibodies in sera from patients with systemic lupus erythematosus (SLE) were characterized by determining cross-reacting specificies with the antigens defined by OKT3, OKT4, OKT8, OKM1 and anti-Ia hybridoma antibodies (Abs). T cells were prepared by sheep erythrocyte (E) rosetting after removal of adherent cells. T cells, or non-T cells, were preincubated with SLE sera at 4°C and then with monoclonal Abs. Binding by specific monoclonal Abs was assessed by two methods: rosetting with ox erythrocytes conjugated with goat anti-mouse IgG and also in the fluorescence-activated cell sorter using fluorescein isothiocyanate-conjugated goat anti-mouse IgG. Using the rosetting method, we found that sera from SLE can block the binding of monoclonal mouse hybridoma anti-Ia Abs to T cells; the blocking of other monoclonal Abs was not consistent. Using fluorescence-activated cell sorter analysis, preincubation with SLE sera lowered the intensity of staining and total percentage of either T or non-T cells stained by monoclonal anti-Ia Abs. Blocking of anti-Ia Abs binding by SLE sera was not histocompatibility leukocyte antigen (HLA)-DR restricted and was not due to Fc receptor binding. These results indicated that antibodies in SLE sera react with structures contiguous to or identical with Ia determinants. Anti-Ia activities in SLE sera correlate with SLE disease activity. In addition, there was a significant negative correlation between anti-Ia blocking activity in the sera and the percentage of Iapositive T cells in the blood of SLE patients. Antibodies in SLE sera with anti-Ia blocking activity may play Dr. Jan L. Ceuppens was supported by a fellowship from the
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Patients with SLE are known to produce antileukocyte antibodies (9) (10) (11) (12) . These antibodies are heterogeneous, with multiple specificities, including normal T and B lymphocyte surface antigens (9) (10) (11) and T cell subsets (12) , and monocytes (13) . Antileukocyte antibodies have been shown to react directly with suppressor cell populations and to block the generation of suppressor cells in vitro (14, 15) .
Recently, there has been great interest in the role of Ia antigens in the regulation of the immune response. These antigens are expressed on B lymphocytes, macrophages, Langerhans cells (16) , and some malignant cells (17, 18) . In addition, Ia antigens have also been found on a small proportion of normal T cells (19) (20) (21) . The percentage of T cells bearing Ia increases after stimulation by mitogens or alloantigens (22) . Functionally, Ia-positive T cells activated by alloantigens have been shown to participate as suppressor cells in vitro (23) . In the present investigation we have found that sera from patients with SLE contain antibodies that block the binding of monoclonal mouse anti-Ia antibodies to T and B cells. These results sug-gest that the anti-Ia blocking activity in SLE sera may play a role in the loss of suppressor cell function in this disease. METHODS SLE patients. Serum samples were collected from 27 patients with SLE. All patients met the American Rheumatism Association criteria for the diagnosis of SLE (24) . Disease activity was assessed at the time blood was collected on the basis of clinical signs of active disease including arthritis, serositis, skin rash, central nervous system involvement, active renal disease, and fever. This assessment was made by the clinician caring for the patient before the results of our laboratory studies were known. After collection, sera were frozen at -20°C in small aliquots. Before use, sera were heated at 56°C for 30 min. In some experiments sera were pepsin-digested at pH 4.0, 37°C, using 2 mg pepsin/ ml of whole serum. After 14 h of pepsin digestion, the precipitate was pelleted in the ultracentrifuge (Sorvall RC2-B, Sorvall Biomedical Div., DuPont Co., Newtown, Conn.) at 20,000 g for 30 (25) . Reactivity with these two anti-T cell reagents was 297%. In addition, T cell preparations showed <1% cells with surface Ig, and <2% peroxidase-positive cells.
In some experiments activated T cells were prepared by incubating E rosette-positive cells for 7 (27) ; OKT4, helperinducer T cells (27) ; OKT8, cytotoxic-suppressor T cells (28) and OKMI, against cells of myelomonocytic origin (29 This reagent (Q-5/13) recognizes an antigenic determinant on the majority of human Ia-like molecules, and does not react with non-Ia-bearing cell lines (31) .
Monoclonal antibody rosetting technique. Bovine erythrocytes were coupled to immunoabsorbent purified goat antimouse IgG (Tago, Inc., Burlingame, Calif.) with the chromic chloride method (32) and resuspended as a 1% suspension in RPMI 1640 with 10% fetal calf serum. Coating of bovine erythrocytes was checked using Coombs reactivity with rabbit anti-goat IgG antiserum. T lymphocytes were incubated with monoclonal antibodies for 30 min at 4°C, were then washed twice with cold phosphate-buffered saline (PBS) in a refrigerated centrifuge (Damon DPR-6000, Damon Corp., Needham Heights, Mass.) resuspended to a concentration of 4 X 106 cells/ml in RPMI + 10% fetal calf serum, and were then mixed with an equal volume of the treated ox erythrocytes. The mixture was centrifuged for 10 min at 200 g, incubated for 30 min on ice, gently resuspended, and the percentage of rosetting cells counted. When antibody-coated ox erythrocytes were incubated with untreated T cells, the percentage of nonspecific rosetting was always <2%.
Immunofluorescence analysis. A cell pellet containing 106 cells was incubated for 30 min on ice with 50 ul of an appropriate dilution of mouse hybridoma monoclonal antibody (2.5-5 Mg/ml) or mouse IgG2 (10lg/ml) purified on Sepharose protein A (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J. 
RESULTS
The capacity of SLE sera to block the binding of monoclonal anti-Ia antibody to a panel of normal resting or activated T cells was assessed by percent rosette inhibition (Table I) . T cells prepared from normal donors by E rosetting techniques were incubated serially with SLE sera at 4°C, followed by addition of monoclonal anti-Ia antibody. The binding of anti-Ia antibody was assessed by rosetting with ox erythrocytes conjugated with goat anti-mouse IgG. In preliminary experiments, we could detect Ia antigens on 11.7±4.0% of unstimulated T cells from 22 normal donors using the rosette method; background percentage of rosetting cells in the presence of SLE sera alone was <1.0% and was not different from NHS (data not shown). As seen in Table I , preincubation with SLE sera caused a substantial decrease in the amount of anti-Ia antibody subsequently bound to the target T cells. This occurred whether resting or activated T cells were used as targets. The degree of inhibition caused by a given SLE sera was similar across several different targets. We also assessed the relation between the inhibition of anti-Ia binding and disease activity. As shown in Fig. 1 , sera from patients with active disease showed a significant anti-Ia blocking effect compared with e See Table I for experimental procedure. The numbers of the SLE patients do not correspond to those in Table I . Percent inhibition of anti-Ia binding is given in parentheses. (Table III) . In addition we found that NHS showed no blocking effect against any of the monoclonal antibodies.
Ia antigen may be closely related to Fc receptors on lymphocyte surface membranes (34); therefore it seemed possible that the blocking of anti-Ia binding by SLE sera might be due to immune complexes in the sera binding to Fc receptors. To evaluate this question, three types of experiments were conducted. First, preincubation of T cells with NHS plus aggregated IgG (500 ,ug/ml) did not block binding of the monoclonal anti-Ia antibody. Second, pepsin digestion of three SLE sera with high anti-Ia blocking effects did not result in a decrease in the blocking of binding of anti-Ia antigens (59±14% inhibition by three untreated SLE sera vs. 59±10% after pepsin digestion). Third, SLE sera showed identical blocking effect on anti-Ia antibodies before and after clearing by ultracentrifugation at 100,000 g for 30 min. In these studies after ultracentrifugation only the upper half of the centrifuged serum sample was tested to insure complete absence of aggregates or complexes. These three sets of experiments suggest that the rosette inhibition effect was not due to Fc binding of immune complexes in SLE sera.
The anti-Ia antibody blocking effect of SLE sera was tested using T cells from three donors of different HLA-DR type. As shown in Table IV , although a slight variation was seen between individuals, the general tendency of blocking was almost the same in each serum. These results indicate that blocking effect found in SLE sera was not HLA-DR restricted. We also compared the sensitivity of the rosette inhibition method to a FACS analysis (Table V) . FACS analysis demonstrated a similar degree of inhibition of binding of anti-Ia by SLE sera as did the rosette technique.
Since Ia antigens are most prominent in B cells and monocytes, the blocking effect of SLE sera was also tested using non-T cells as targets. These experiments were done using FACS analysis because the rosette inhibition technique could not be applied due to nonspecific rosetting of B cell fractions. A representative blocking pattern of one SLE serum is presented in Fig. 2. After preincubation with SLE serum, the percentage of cells staining with anti-Ia antibody decreased from 63.7% to 43.0%. In addition, Fig. 1 illustrates a striking downward shift in intensity of staining by the anti-Ia antibody. Not shown in this figure, the percentage of 20 Okudaira, Searles, Ceuppens, Goodwin, and Williams the most intensely staining cells in the last channel of the FACS decreased from 10.5% with NHS to 1% with SLE sera. Therefore it appeared that the anti-Ia blocking activity in SLE sera is not restricted to Ia antigens on T cells only.
Yu et al. (35) have reported an increase in Ia(+) T cells in the peripheral blood of patients with SLE. Therefore we examined the relationship between antiIa blocking activity in the sera and Ia(+) T cells in the blood of 10 patients with SLE. The results, shown in Fig. 3 , demonstrate a significant inverse relationship between anti-Ia blocking activity in sera and the percentage of Ia(+) T cells in blood. In addition, the SLE patients with active disease (open circles) had a significantly lower percentage of Ia(+) T cells (6.1±0.8, mean±SEM) than did inactive patients (13.7±1.0, P < 0.02) or 22 normal controls (11.7±0.8, P < 0.02). (38) .
Thus selective reactivity of SLE sera for OKT8(+) T cells may be directly related to anti-Ia specificity. This specificity may also be related to anti-Ty cell reactivity noted in some SLE sera (39) since Ia(+) T cells appear to be largely Ty cells (21, 40) .
Messner et al. (41) reported that lymphocytotoxic activity of sera from SLE patients and their families was inhibited by preincubation of the target peripheral blood mononuclear cells with F(ab)'2 fragments of xenoantisera against 32-microglobulin or the heavy chains of the HLA-A, B, C antigenic molecular complex. On the other hand, anti-HLA-DR xenoantiserum did not block cytotoxicity by SLE sera against peripheral blood mononuclear cells. The discrepancy between our data and theirs may be due to the differential sensitivity of the assay systems used. We used two different systems, a rosette method and FACS assay. Both methods showed substantial blocking by SLE sera of the binding of anti-Ia antibody to T cells or to non-T cells. This was shown most strikingly in Fig. 2 , illustrating a FACS analysis using non-T cells.
Activated T cells in allogenic culture have been reported to inhibit a subsequent mixed lymphocyte response (42, 43) and Ia(+) T cells mainly participate in this suppression (23) . Considering that Ia-positive T cells are mostly contained in the T-y cell fraction (21, 40) , these anti-Ia SLE reactive antibodies may cause the decrease of Ty cells found in active SLE patients. This conclusion is consistent with our previous findings that IgG anti Ty cell antibody in SLE sera can block the induction of suppressor cells (44) .
Furthermore, the autologous mixed lymphocyte response in which T cells respond to autologous non-T (45) . This reaction, which is decreased in SLE (46, 47) , has been proposed as a mechanism by which T cells regulate lymphocyte function. We are presently studying the possibility that the decreased autologous mixed lymphocyte response in these autoimmune diseases might be caused by antiIa reactivity in patients' sera.
